Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05237297
Other study ID # IL49NS01
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date February 17, 2022
Est. completion date July 27, 2022

Study information

Verified date June 2023
Source Il-Yang Pharm. Co., Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study evaluate the pharmacokinetic drug interactions and safety after co-administration of ilaprazole and NSAID in healthy adults.


Recruitment information / eligibility

Status Completed
Enrollment 72
Est. completion date July 27, 2022
Est. primary completion date July 13, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 19 Years to 55 Years
Eligibility Inclusion Criteria: 1. Healthy adults aged 19 or older and 55 or younger at the time of screening tests. 2. Men weigh more than 55 kg and women weigh more than 50 kg. 3. Those who have a body mass index of 18.5 kg/m2 or more and less than 27.0 kg/m2. ? Body mass index (kg/m2) = Weight (kg)/[Height (m)]2 4. If participants are a woman, participants must apply to one of the following. - Menopausal (no natural menstruation for at least 2 years) - Surgical infertility (autonomous exudation or bilateral ovarian resection, intubation ligation, or other infertility) 5. Men who have sexual relationship with women of child bearing potential must give consent to using contraceptive measures(condoms, spermicide, and menstrual cycle control) for at least 28 days after the final administration of clinical trial and clinical drugs (if the male test subject or female partner is infertile, the above contraception is unnecessary). 6. A person who has heard sufficient explanation of this clinical trial and fully understood it, voluntarily decided to participate, and agreed in writing to comply with precautions. Exclusion Criteria: 1. A person with a history of mental illness or illness corresponding to clinically significant hepatobiliary tract (hepatic liver disorder, kidney (severe renal disorder, etc.), nervous system, immune system, respiratory system (bronchial asthma, etc.), urinary system, digestive system, endocrine blood and tumor, cardiovascular system (severe high blood pressure, heart failure, etc.). 2. Active peptic ulcer/bleeding or a person with a medical history. 3. A person who tends to bleed or have a blood clotting disorder. 4. Patients with a history of gastrointestinal bleeding or perforation due to NSAID treatment in the past. 5. Those with a history of gastrointestinal diseases (Crohn's disease, ulcerative colitis, etc.) or surgery (except for simple appendectomy or hernia surgery) that can affect the absorption of drugs. 6. Person with a history of significant drug hypersensitivity reactions to the ingredients and additives of clinical trial drugs. In particular, NSAIDs and aspirin such as Yellow No. 4 (Tartrazine), Yellow No. 5 (Sunset Yellow FCF), sulfonamide, ilaprazole and naproxen, aceclofenac, celecoxib, diclofenac, etc. 7. A person with a history of asthma, rhinitis, and nasal polyps due to aspirin or other NSAIDs (including COX-2 inhibitors). 8. Those with genetic problems such as galactose intolerance, Lap lactase deficiency, or glucose-galactose malabsorption. 9. A person who was judged to be inappropriate as a test subject in a screening test conducted within 28 days before the first administration date of the clinical trial drug. - In the case of > 1.25 times the upper limit of AST and ALT normal range in the blood, - When the potassium concentration in the blood exceeds 5.5 mEq/L, - Estimated Global Film Rate (eGFR) <60 mL/min/1.73 m2 using the Modification of Diet in Regular Disease (MDRD) formula - Immunology and serology tests (hepatitis B test, hepatitis C test, human immunodeficiency virus (HIV) test, syphilis test) result are positive factors. - After resting for more than 5 minutes, systolic blood pressure >150 mmHg or << in vital signs measured at the seat> Those who showed values corresponding to 90 mmHg, dilator blood pressure >100 mmHg, or <50 mmHg. 10. A person who has a history of drug abuse or has tested positive in a urine drug screening test within one year of screening. 11. If the tester determines that the following drugs, excluding topical drugs without significant systemic absorption, may affect this test or affect the safety of the test subject within the relevant period, - In the case of taking a prescription drug or herbal medicine within 14 days prior to the first administration date of the clinical trial drug, - In the case of taking general medicines including health foods and vitamin preparations within 7 days prior to the first administration of clinical trial drugs, - A person who took drugs such as barbital drugs and other drugs inducing and inhibiting drugs within 30 days prior to the first administration of clinical trial drugs. 12. A person who continuously smoked excessively or consumed caffeine or alcohol (caffeine: >5 cups/day, alcohol: >210 g/week, tobacco: >10 g/day) or who cannot stop smoking, caffeine and alcohol consumption during each hospitalization period. 13. A person who has consumed grapefruit-containing food within 7 days prior to the first administration date of clinical trial drugs or cannot be prohibited from taking it during the clinical trial period. 14. A person who participated in another clinical trial within 180 days prior to the first administration date of the clinical trial drug and received the clinical trial drug (in the case of biological agents, it may be based on an extended period considering a half-life). 15. A person who donated whole blood within 60 days prior to the first administration date of clinical trial drugs or donated component blood within 30 days. 16. A person who received a blood transfusion within 30 days prior to the first administration date of the clinical trial drug. 17. Pregnant or lactating women. 18. A person who determines that the tester is inappropriate to participate in clinical trials due to other reasons.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Ilaprazole
Ilaprazole 10mg
Naproxen
Naproxen 500mg
Aceclofenac
Aceclofenac 100mg
Celecoxib
Celecoxib 200mg

Locations

Country Name City State
Korea, Republic of Severance Hospital Seoul

Sponsors (1)

Lead Sponsor Collaborator
Il-Yang Pharm. Co., Ltd.

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary Part 1 ilaprazole, naproxen Cmax,ss(Maximum concentration of drug in plasma at steady state) Predose(0hour), after dose 0.5hour, 0.75hour, 1hour, 1.5hours, 2hours, 2.5hours, 3hours, 3.5hours, 4hours, 5hours, 6hours, 8hours, 10hours, 12hours
Primary Part 1 ilaprazole, naproxen AUCtau,ss(Area under the plasma drug concentration-time curve within a dosing interval (tau) at steady state) Predose(0hour), after dose 0.5hour, 0.75hour, 1hour, 1.5hours, 2hours, 2.5hours, 3hours, 3.5hours, 4hours, 5hours, 6hours, 8hours, 10hours, 12hours
Primary Part 2 ilaprazole, aceclofenac Cmax,ss(Maximum concentration of drug in plasma at steady state) Predose(0hour), after dose 0.5hour, 0.75hour, 1hour, 1.5hours, 2hours, 2.5hours, 3hours, 3.5hours, 4hours, 5hours, 6hours, 8hours, 10hours, 12hours
Primary Part 2 ilaprazole, aceclofenac AUCtau,ss(Area under the plasma drug concentration-time curve within a dosing interval (tau) at steady state) Predose(0hour), after dose 0.5hour, 0.75hour, 1hour, 1.5hours, 2hours, 2.5hours, 3hours, 3.5hours, 4hours, 5hours, 6hours, 8hours, 10hours, 12hours
Primary Part 3 ilaprazole, celecoxib Cmax,ss(Maximum concentration of drug in plasma at steady state) Predose(0hour), after dose 1hour, 1.5hours, 2hours, 2.5hours, 3hours, 3.5hours, 4hours, 5hours, 6hours, 8hours, 10hours, 12hours
Primary Part 3 ilaprazole, celecoxib AUCtau,ss(Area under the plasma drug concentration-time curve within a dosing interval (tau) at steady state) Predose(0hour), after dose 1hour, 1.5hours, 2hours, 2.5hours, 3hours, 3.5hours, 4hours, 5hours, 6hours, 8hours, 10hours, 12hours
Secondary Part 1. ilaprazole, naproxen Tmax,ss(Time to maximum plasma concentration at steady state) Predose(0hour), after dose 0.5hour, 0.75hour, 1hour, 1.5hours, 2hours, 2.5hours, 3hours, 3.5hours, 4hours, 5hours, 6hours, 8hours, 10hours, 12hours
Secondary Part 1. ilaprazole, naproxen CLss/F(Apparent clearance of drug in plasma at steady state) Predose(0hour), after dose 0.5hour, 0.75hour, 1hour, 1.5hours, 2hours, 2.5hours, 3hours, 3.5hours, 4hours, 5hours, 6hours, 8hours, 10hours, 12hours
Secondary Part 1. ilaprazole, naproxen Vdss/F(Apparent volume of distribution at steady state) Predose(0hour), after dose 0.5hour, 0.75hour, 1hour, 1.5hours, 2hours, 2.5hours, 3hours, 3.5hours, 4hours, 5hours, 6hours, 8hours, 10hours, 12hours
Secondary Part 1. ilaprazole, naproxen Cmin,ss(Minimum concentration of drug in plasma at steady state) Predose(0hour), after dose 0.5hour, 0.75hour, 1hour, 1.5hours, 2hours, 2.5hours, 3hours, 3.5hours, 4hours, 5hours, 6hours, 8hours, 10hours, 12hours
Secondary Part 1. ilaprazole, naproxen fluctuation Predose(0hour), after dose 0.5hour, 0.75hour, 1hour, 1.5hours, 2hours, 2.5hours, 3hours, 3.5hours, 4hours, 5hours, 6hours, 8hours, 10hours, 12hours
Secondary Part 2. ilaprazole, aceclofenac Tmax,ss(Time to maximum plasma concentration at steady state) Predose(0hour), after dose 0.5hour, 0.75hour, 1hour, 1.5hours, 2hours, 2.5hours, 3hours, 3.5hours, 4hours, 5hours, 6hours, 8hours, 10hours, 12hours
Secondary Part 2. ilaprazole, aceclofenac CLss/F(Apparent clearance of drug in plasma at steady state) Predose(0hour), after dose 0.5hour, 0.75hour, 1hour, 1.5hours, 2hours, 2.5hours, 3hours, 3.5hours, 4hours, 5hours, 6hours, 8hours, 10hours, 12hours
Secondary Part 2. ilaprazole, aceclofenac Vdss/F(Apparent volume of distribution at steady state) Predose(0hour), after dose 0.5hour, 0.75hour, 1hour, 1.5hours, 2hours, 2.5hours, 3hours, 3.5hours, 4hours, 5hours, 6hours, 8hours, 10hours, 12hours
Secondary Part 2. ilaprazole, aceclofenac Cmin,ss(Minimum concentration of drug in plasma at steady state) Predose(0hour), after dose 0.5hour, 0.75hour, 1hour, 1.5hours, 2hours, 2.5hours, 3hours, 3.5hours, 4hours, 5hours, 6hours, 8hours, 10hours, 12hours
Secondary Part 2. ilaprazole, aceclofenac fluctuation Predose(0hour), after dose 0.5hour, 0.75hour, 1hour, 1.5hours, 2hours, 2.5hours, 3hours, 3.5hours, 4hours, 5hours, 6hours, 8hours, 10hours, 12hours
Secondary Part 3. ilaprazole, celecoxib Tmax,ss(Time to maximum plasma concentration at steady state) Predose(0hour), after dose 1hour, 1.5hours, 2hours, 2.5hours, 3hours, 3.5hours, 4hours, 5hours, 6hours, 8hours, 10hours, 12hours
Secondary Part 3. ilaprazole, celecoxib CLss/F(Apparent clearance of drug in plasma at steady state) Predose(0hour), after dose 1hour, 1.5hours, 2hours, 2.5hours, 3hours, 3.5hours, 4hours, 5hours, 6hours, 8hours, 10hours, 12hours
Secondary Part 3. ilaprazole, celecoxib Vdss/F(Apparent volume of distribution at steady state) Predose(0hour), after dose 1hour, 1.5hours, 2hours, 2.5hours, 3hours, 3.5hours, 4hours, 5hours, 6hours, 8hours, 10hours, 12hours
Secondary Part 3. ilaprazole, celecoxib Cmin,ss(Minimum concentration of drug in plasma at steady state) Predose(0hour), after dose 1hour, 1.5hours, 2hours, 2.5hours, 3hours, 3.5hours, 4hours, 5hours, 6hours, 8hours, 10hours, 12hours
Secondary Part 3. ilaprazole, celecoxib fluctuation Predose(0hour), after dose 1hour, 1.5hours, 2hours, 2.5hours, 3hours, 3.5hours, 4hours, 5hours, 6hours, 8hours, 10hours, 12hours
See also
  Status Clinical Trial Phase
Completed NCT03789032 - Study to Evaluate the Effect of Rabeprazole on the Pharmacokinetics of Vadadustat Phase 1
Completed NCT03706222 - Drug-Drug Interactions of Grazoprevir/Elbasvir in Taiwan
Completed NCT02191358 - YouScript IMPACT Registry N/A
Completed NCT02485028 - Pharmacokinetic Interaction Study of Dapoxetine 30mg and Mirodenafil 50mg Phase 1
Completed NCT01896557 - Ranitidin Versus Omeprazole in Patients Taking Clopidogrel Phase 4
Completed NCT03011463 - Pharmacokinetic Interaction Between Trospium With an Inhibitor of OCT1 and of P-gp in Subjects Genotyped for OCT1 Phase 1
Completed NCT02485041 - Pharmacokinetic Interaction Study of Dapoxetine 30mg and Mirodenafil 100mg Phase 1
Completed NCT01477411 - A Drug-Drug Interaction Study of Digoxin and PA21 Phase 1
Completed NCT01477424 - A Drug-Drug Interaction Study of Warfarin and PA21 Phase 1
Completed NCT05558150 - Study to Evaluate Pharmacokinetic Drug Interactions and Safety of Ilaprazole and Aceclofenac Phase 1
Completed NCT03493698 - A Fixed-Sequence, Drug-Drug Interaction Study Between Multiple Oral Doses of Inarigivir Soproxil and a Single Oral Dose of Midazolam in Healthy Subjects Phase 1
Completed NCT03126578 - Open-label, Single Center, Non-randomized, Fixed Sequence Phase 1 Drug-drug Interaction Study With LEO 32731 and Midazolam Phase 1
Completed NCT01369186 - Drug Drug Interactions of Aspirin and P2Y12-inhibitors Phase 4
Completed NCT02378220 - Pharmacogenetic Testing Among Home Health Patients N/A
Completed NCT01324752 - A Drug-Drug Interaction Study of Losartan and PA21 Phase 1
Completed NCT02500667 - A Drug-Drug Interaction Study of N91115 +/- Rifampin in Healthy Adult Subjects Phase 1
Completed NCT03801733 - Drug-Drug Interaction Study of Vadadustat With Rosuvastatin, Sulfasalazine, Pravastatin, Atorvastatin and Simvastatin Phase 1
Completed NCT03801759 - Drug-Drug Interaction Study of Vadadustat With Digoxin, Adefovir and Furosemide Phase 1
Completed NCT03801746 - Drug-Drug Interaction Study of Vadadustat With Cyclosporine, Probenecid and Rifampin Phase 1
Completed NCT01736371 - Analysis of Cisatracurium Consumption in Balanced Anesthesia With 1% Sevoflurane, and With Only Sevoflurane, Using a Closed-loop Computer Controlled System Infusion. N/A